Article
Oncology
Gabriel B. Mpilla, Md Hafiz Uddin, Mohammed N. Al-Hallak, Amro Aboukameel, Yiwei Li, Steve H. Kim, Rafic Beydoun, Gregory Dyson, Erkan Baloglu, William T. Senapedis, Yosef Landesman, Kay-Uwe Wagner, Nerissa T. Viola, Bassel F. El-Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi
Summary: The study highlights the need for more effective targeted approaches to sensitize PNETs to everolimus for better treatment outcomes. The dual inhibitor KPT-9274 targeting PAK4-NAMPT, when combined with everolimus, showed promising results in inhibiting PNET growth and formation.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Antonio Viudez, Guillermo Crespo, Maria Luisa Gomez Dorronsoro, Imanol Arozarena, Juan Jesus Marin-Mendez, Ana Custodio, Marta Benavent, Saioa Goni, Beatriz Garcia-Paredes, Jorge Hern, Maika Durantez, Vicente Alonso, Del Carmen Riesco, Carlos Lopez, Paula Jimenez-Fonseca, Borja Lopez San Vicente, Iranzu Gonzalez-Borja, Isabel Sevilla, Irene Hernandez-Garcia, Alberto Carmona-Bayonas, Jaume Capdevila, Jairo Perez-Sanz, Rocio Garcia-Carbonero, Leyre Perez-Ricarte, Marta Llanos, Ruth Vera, Ana De Jesus Acosta
Summary: Through immunohistochemistry expression evaluation, it was found that a simple immunohistochemistry prognostic score (IPS) could serve as an effective indicator for predicting the prognosis of patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide.
Article
Oncology
Nitya Raj, Youyun Zheng, Haley Hauser, Joanne Chou, Johnathan Rafailov, Jad Bou-Ayache, Peter Sawan, Jamie Chaft, Jennifer Chan, Kimberly Perez, Charles Rudin, Laura Tang, Diane Reidy-Lagunes
Summary: The combination of ribociclib and everolimus had insufficient activity in treating foregut WDNETs, failing to meet the criteria for further investigation. No patients experienced an objective response, and the median progression-free survival was 7.7 months. High rates of myelosuppression led to treatment interruptions and dose reductions in a majority of patients. Genetic testing did not identify a predictive biomarker for disease stabilization in this study.
ENDOCRINE-RELATED CANCER
(2021)
Review
Oncology
Aman Chauhan, Jaydira Del Rivero, Robert A. Ramirez, Heloisa P. Soares, Daneng Li
Summary: Neuroendocrine tumors (NETs) are increasingly common, and the treatment options for advanced NETs are evolving rapidly. However, there is limited data on how different treatments should be sequenced. This review assesses clinical trial data and provides expert perspectives on treatment sequencing for various clinical scenarios. The best practices provided in this review can be helpful for clinicians considering treatment options for their patients with advanced NETs.
Article
Radiology, Nuclear Medicine & Medical Imaging
Damiano Caruso, Michela Polici, Maria Rinzivillo, Marta Zerunian, Ilaria Nacci, Matteo Marasco, Ludovica Magi, Mariarita Tarallo, Simona Gargiulo, Elsa Iannicelli, Bruno Annibale, Andrea Laghi, Francesco Panzuto
Summary: The aim of this study was to test the radiomic approach in patients with metastatic neuroendocrine tumors (NETs) treated with Everolimus, and the results showed that radiomics could be used as an imaging biomarker to predict progression-free survival (PFS) and death.
Article
Oncology
Pamela T. Kunz, Noah T. Graham, Paul J. Catalano, Halla S. Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew E. Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, Edmond L. Schmulbach, Diane L. Reidy-Lagunes, Jonathan R. Strosberg, Peter J. O'Dwyer, Al B. Benson
Summary: In patients with advanced pancreatic neuroendocrine tumors (NETs), the combination of capecitabine and temozolomide showed significant improvement in progression-free survival compared to temozolomide alone. This combination therapy achieved the highest reported median progression-free survival and response rate in a randomized study for pancreatic NETs.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
T. Cascone, R. L. Sacks, I. M. Subbiah, N. Drobnitzky, S. A. Piha-Paul, D. S. Hong, K. R. Hess, B. Amini, T. Bhatt, S. Fu, A. Naing, F. Janku, D. Karp, G. S. Falchook, A. P. Conley, S. Sherman, F. Meric-Bernstam, A. J. Ryan, J. Heymach, V Subbiah
Summary: The combination therapy of VAN + EV shows promising antitumor activity in advanced solid cancers, with manageable toxicities. Further studies are needed to explore its efficacy in tumors with RET pathway aberrations.
Article
Cardiac & Cardiovascular Systems
Lara Girelli, Monica Casiraghi, Alberto Sandri, Francesco Petrella, Domenico Galetta, Roberto Gasparri, Patrick Maisonneuve, Nicola Fazio, Lorenzo Spaggiari
Summary: Surgical resection remains the treatment of choice for bronchial carcinoids with good prognosis, while aggressive forms like LCNEC with lymph nodal metastasis have a poor prognosis and require aggressive multidisciplinary treatment.
ANNALS OF THORACIC SURGERY
(2021)
Article
Oncology
Chiara Alessandra Cella, Francesca Spada, Alfredo Berruti, Francesco Bertolini, Patrizia Mancuso, Massimo Barberis, Eleonora Pisa, Manila Rubino, Lorenzo Gervaso, Alice Laffi, Stefania Pellicori, Davide Radice, Laura Zorzino, Angelica Calleri, Luigi Funicelli, Giuseppe Petralia, Nicola Fazio
Summary: The early identification of resistant tumors remains a major challenge in the treatment of pancreatic neuroendocrine tumors (PanNETs). This study evaluated a specific angiogenesis panel as possible predictors of resistance to everolimus or everolimus efficacy in PanNETs. The findings suggest that circulating endothelial progenitors might be surrogate biomarkers for angiogenesis activity in PanNETs during everolimus treatment.
Article
Medicine, Research & Experimental
Jacques Greenberg, Jessica Limberg, Akanksha Verma, David Kim, Xiang Chen, Yeon J. Lee, Maureen D. Moore, Timothy M. Ullmann, Jessica W. Thiesmeyer, Zachary Loewenstein, Kevin J. Chen, Caitlin E. Egan, Dessislava Stefanova, Rohan Bareja, Rasa Zarnegar, Brendan M. Finnerty, Theresa Scognamiglio, Yi-Chieh Nancy Du, Olivier Elemento, Thomas J. Fahey III, Irene M. Min
Summary: This study investigates the therapeutic options for metastatic pancreatic neuroendocrine tumors (PNETs). The results suggest that remodeling the tumor microenvironment (TME) may enhance susceptibility to immunotherapy. The TMEs of localized and metastatic PNETs were analyzed, revealing activation of inflammatory and immune-related pathways in metastatic tumors. Additionally, a histone deacetylase inhibitor, vorinostat, was shown to increase chemokine expression and enhance recruitment of T cells in PNET tissues.
Article
Oncology
Julie E. Bauman, Zhengjia Chen, Chao Zhang, James P. Ohr, Robert L. Ferris, Gerald M. McGorisk, Stephen Brandt, Sumathi Srivatsa, Amy Y. Chen, Conor E. Steuer, Dong M. Shin, Nabil F. Saba, Fadlo R. Khuri, Taofeek K. Owonikoko
Summary: This randomized trial showed that the combination of everolimus and pasireotide-LAR is more effective in treating thyroid cancer compared to a single agent. Delayed use of this combination strategy appeared to be promising in achieving optimal efficacy.
Article
Oncology
Tanios S. Bekaii-Saab, Rona Yaeger, Alexander I. Spira, Meredith S. Pelster, Joshua K. Sabari, Navid Hafez, Minal Barve, Karen Velastegui, Xiaohong Yan, Aditya Shetty, Hirak Der-Torossian, Shubham Pant
Summary: The study evaluated the clinical activity and safety of adagrasib in patients with other solid tumors harboring a KRAS(G12C) mutation. The results demonstrated encouraging clinical activity and good tolerability of adagrasib in this rare cohort of pretreated patients with KRAS(G12C)-mutated solid tumors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ali Aljubran, Ahmed Badran, Mohamed Alrowaily, Hussein Raef, Ahmed M. Alzahrani, Ahmed Almuhaideb, Hadeel Almanea, Abdelmoneim El-Dali, Mahmoud Tuli, Shouki Bazarbashi
Summary: This study aimed to evaluate the safety and efficacy of combining everolimus and PRRT in the treatment of unresectable NETs. However, the trial was terminated early due to poor accrual. The combination of everolimus at a dose of 10 mg daily and Lu-177-DOTATATE appears not to be feasible. A larger trial at a lower dose of everolimus is warranted.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2022)
Article
Immunology
Yu-Xiang Ma, Fu-Rong Liu, Yang Zhang, Qun Chen, Zhi-Qiang Chen, Qian-Wen Liu, Yan Huang, Yun-Peng Yang, Wen-Feng Fang, Ning Xi, Ning Kang, Yu-Lei Zhuang, Qi Zhang, Ying-Zhi Jiang, Li Zhang, Hong-Yun Zhao
Summary: CT053PTSA is a novel tyrosine kinase inhibitor that shows promising antitumor and antiangiogenic activity. The first-in-human study demonstrated that CT053PTSA is well tolerated and has a satisfactory safety profile. Further clinical trials are ongoing to evaluate the clinical activity of CT053PTSA.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K. Williamson, Joaquina Baranda, Hirva Mamdani, Ya-Li Lee, Li Li, Xingli Wang, Xunwei Dong
Summary: FN-1501, a novel intravenous FLT3 inhibitor, has shown potential efficacy and safety for patients with advanced solid tumors. The maximum tolerated dose (MTD) of FN-1501 was determined to be 170 mg, demonstrating reasonable safety, tolerability, and preliminary activity against solid tumors.